What is the current stock price of Eagle Pharmaceuticals, Inc. (EGRX)?

As of the latest market data, Eagle Pharmaceuticals, Inc. (EGRX) is trading at $0.23. The stock has seen a gain of 12.53% today.

Does Eagle Pharmaceuticals, Inc. (EGRX) pay a dividend?

Based on current data, Eagle Pharmaceuticals, Inc. does not have a confirmed active dividend policy.

What is the market cap of Eagle Pharmaceuticals, Inc.?

The current market capitalization of Eagle Pharmaceuticals, Inc. (EGRX) is approximately unavailable.

EGRX

Eagle Pharmaceuticals, Inc.·Healthcare

0.23

12.525%(+0.03)

Market Closed

2.33

935.325%(+2.10)

After Hours

Last Updated: — ET

52W L: $0.0952W H: $3.87

EGRX NEWS

prnewswire.com

2d ago

Did Eagle Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

defenseworld.net

Mar 31

Eagle Pharmaceuticals (NASDAQ:EGRX) Shares Pass Above 50-Day Moving Average – Should You Sell?

Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX - Get Free Report) shares passed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $0.26 and traded as high as $0.3411. Eagle Pharmaceuticals shares last traded at $0.3411, with a volume of 104 shares. Eagle Pharmaceuticals Stock Performance The company has

globenewswire.com

Jan 14

Eagle Pharmaceuticals Announces Divestiture of Barhemsys

WOODCLIFF LAKE, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the divestiture of the marketing authorization for Barhemsys (amisulpride) in the U.S. to LXO Group, Paris, France.

Company Profile

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

134

IPO Date

2014-02-12

Beta

0.31

Websitewww.eagleus.com↗